Gotham Asset Management LLC Has $48.72 Million Stake in Biogen Inc. $BIIB

Gotham Asset Management LLC boosted its position in Biogen Inc. (NASDAQ:BIIB) by 2.3% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 276,809 shares of the biotechnology company’s stock after purchasing an additional 6,311 shares during the period. Gotham Asset Management LLC’s holdings in Biogen were worth $48,716,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BIIB. Norges Bank bought a new stake in Biogen in the fourth quarter valued at $464,408,000. Boston Partners bought a new stake in Biogen in the 4th quarter valued at about $302,815,000. Fred Alger Management LLC increased its position in Biogen by 39,074.8% in the 4th quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock valued at $140,576,000 after buying an additional 796,735 shares in the last quarter. Orion Porfolio Solutions LLC increased its position in Biogen by 6,828.4% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock valued at $64,965,000 after buying an additional 509,809 shares in the last quarter. Finally, Caisse de depot et placement du Quebec increased its position in Biogen by 718.2% in the 3rd quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company’s stock valued at $79,741,000 after buying an additional 499,676 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Biogen Trading Up 1.6%

NASDAQ:BIIB opened at $198.67 on Thursday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The firm has a 50-day moving average of $190.05 and a 200-day moving average of $184.70. The company has a market cap of $29.33 billion, a PE ratio of 21.32 and a beta of 0.20. Biogen Inc. has a one year low of $121.05 and a one year high of $205.97.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the previous year, the firm posted $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities research analysts expect that Biogen Inc. will post 13.89 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BIIB. Royal Bank Of Canada boosted their target price on Biogen from $222.00 to $227.00 and gave the company an “outperform” rating in a research report on Wednesday, May 27th. Argus raised Biogen to a “hold” rating in a research report on Thursday, April 9th. The Goldman Sachs Group boosted their target price on Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Mizuho decreased their target price on Biogen from $236.00 to $221.00 and set an “outperform” rating for the company in a research report on Monday. Finally, Needham & Company LLC raised Biogen from a “hold” rating to a “buy” rating and set a $255.00 target price for the company in a research report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Biogen currently has an average rating of “Moderate Buy” and a consensus price target of $216.70.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.